Human microbiome

The BioCollective® Awarded Groundbreaking Probiotic Patent

Retrieved on: 
Thursday, March 7, 2024
Ecology, The, Diabetes, Parkinson's disease, Probiotic, Human microbiome, Carbohydrate metabolism, Pediococcus acidilactici, Blood, Patent, Use, Disease, Health, Type 2 diabetes, Triglyceride, Leuconostoc mesenteroides, DSM-IV codes, Patient, Insulin, United States patent law, Clinical trial, Research, Dietary supplement

DENVER, March 7, 2024 /PRNewswire-PRWeb/ -- The BioCollective, a pioneer in microbiome research and consumer probiotics, today announced it has been granted a patent for a system of probiotics to manage and potentially treat a range of significant health issues.

Key Points: 
  • The issued composition-of-matter patent covers probiotic formulations to prevent or limit disease conditions, restore lost physiological function, and reduce gastrointestinal infection by modulating gastrointestinal mannitol.
  • The patent covers a range of clinical conditions, including diabetes, metabolic diseases, gastrointestinal infections, and neurological diseases.
  • The US Patent and Trademark Office issued US Patent No.
  • The company's BiotiQuest® Sugar Shift® probiotic and additional products in its development pipeline are covered under the patent.

Global Microbiome Targeting Therapeutics in Infectious Diseases Report 2022: Featuring Rebiotix, Nexbiome Therapeutics, Finch Therapeutics and Evelo Biosciences Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, January 16, 2023
Fitness & Nutrition, Health, CDI, IO, Therapy, COVID-19, LBP, Human microbiome, Infection, FMT, Cancer, Clostridioides difficile infection, Clostridioides, Antibiotics

The "Microbiome-Targeting Therapeutics in Infectious Diseases - Thematic Research" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Microbiome-Targeting Therapeutics in Infectious Diseases - Thematic Research" report has been added to ResearchAndMarkets.com's offering.
  • There are currently 23 drugs in clinical development that target the microbiome for ID indications in the 7MM.
  • Ten out of the 23 drugs (43%) are in in clinical development for Clostridioides difficile infections (CDI).
  • Rebiotix Inc currently holds the most potential in the microbiome space for infectious diseases, with two drug candidates under development across 4 different indications.

Outlook on the Irritable Bowel Syndrome Treatment Global Market to 2027 - Improving Diagnostic Modalities and Easy Access to Healthcare Services is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 13, 2022
Health, General Health, Cramp, CBT, Loperamide, Constipation, Weight loss, Risk, Growth, Infection, Diarrhea, Patient, Rifaximin, Abdominal pain, Depression, Research, Sustainable Development Goals, Lists of diseases, Human microbiome, Degenerative disease, Laxative, R, Probiotic, FMT, Vomiting, IBS, Somatic symptom disorder, Anxiety, Irritable bowel syndrome, Smart contract, COVID-19, Bloating, Nervous system, Sustainable Development Goal 2, Pharmaceutical industry

Irritable bowel syndrome (IBS) refers to a chronic medical condition that affects the large intestine.

Key Points: 
  • Irritable bowel syndrome (IBS) refers to a chronic medical condition that affects the large intestine.
  • It is usually caused by severe infection, stressful lifestyle, changes in gut microbes, muscle contractions in the intestine, and abnormalities in the nervous system.
  • This, along with improving diagnostic modalities and easy access to healthcare services, represents one of the key factors bolstering the growth of the market.
  • The publisher provides an analysis of the key trends in each sub-segment of the global irritable bowel syndrome treatment market report, along with forecasts at the global, regional and country level from 2022-2027.

Global Microbiome Therapeutics Market Analysis Report 2021-2032: Focus on Target Therapies, Region (10 Countries), and Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 28, 2022
Health, Biotechnology, Seminal vesicles, Name, Region, Infection, Awareness, Human microbiome, Piper LBP, Competitive landscape, Microbiome, Research, COVID-19, Benchmarking, Adoption, CAGR, Organization, Review, FMT, Disease, CDI, Therapy, Growth, Attention, Natural growth promoter, Population, Medical device, Dietary supplement, Antibiotics, Fine chemical

The "Global Microbiome Therapeutics Market - A Global and Regional Analysis: Focus on Target Therapies, Region (10 Countries), and Competitive Landscape - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Microbiome Therapeutics Market - A Global and Regional Analysis: Focus on Target Therapies, Region (10 Countries), and Competitive Landscape - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • The existing microbiome therapeutics market is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market.
  • Moreover, a detailed competitive benchmarking of the players operating in the global microbiome therapeutics market has been done to help the reader understand how players stand against each other, presenting a clear market landscape.
  • Even though these measures were necessary, it had mostly negative impact on the Global microbiome therapeutics market.

Biomica Appoints Professor Gal Markel to Company's Scientific Advisory Board

Retrieved on: 
Thursday, July 28, 2022
Eleazar Sukenik, Knowledge, Computation, Doctor of Philosophy, Human microbiome, Medicine, Hebrew University of Jerusalem, CPB, Coronavirus Scientific Advisory Board (Turkey), Melanoma, Rabin Medical Center, CSO, Tel Aviv University, NASDAQ, Cancer, Immunotherapy, Merck, MBA, Clalit Health Services, Sheba Medical Center, MD, Merck & Co., TASE, BTC, Patient, Therapy, Faculty, Medical school, IDC, Pharmaceutical industry, Antibiotics, Science

REHOVOT, Israel, July 28, 2022 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced that Professor Gal Markel, Director of the Davidoff Cancer Center & Deputy Director General of the Rabin Medical Center at Clalit Health Services in Israel, is joining Biomica's Scientific Advisory Board.

Key Points: 
  • Professor Markel is an internationally recognized expert in translational tumor immunology and clinical immuno-oncology.
  • Prof. Markel co-founded BTC (acquired by DSPG in 2011), was the scientific founder and Chief Scientific Officer of cCAM Biotherapeutics (acquired by Merck & Co in 2015) and 4C Biomed.
  • Professor Gal Markel said: "I am very excited to join Biomica's superb team and contribute to the development of its unique microbiome-based therapeutics for cancer patients.
  • Professor Yehuda Ringel, CSO and Chairman of the Scientific Advisory Board, commented: "I am very pleased that Professor Markel has chosen to join our advisory board.

Microbiome Global (FMT, Microbiome Drugs) Market Report 2022 Featuring Major Players - MicroBiome Therapeutics; Seres Therapeutics; Enterome Bioscience; Second Genome; Vedanta Biosciences - ResearchAndMarkets.com

Retrieved on: 
Friday, June 17, 2022
Health, Biotechnology, Multiple sclerosis, Prevalence, Solution, Metabolomics, FMT, Seed, Crohn's disease, Infection, Inflammatory bowel disease, Probiotic, Genomics, Technology, Transplant, Reproductive health, Insurance, Recurrence, Proteomics, Oxidative stress, Ulcerative colitis, Growth, Rheumatoid arthritis, IBD, Acquisition, Quality of life, Human microbiome, Patient, Fecal microbiota transplant, Application, Diabetes, UC, Novozymes, Risk, Dietary supplement, Antibiotics

The "Microbiome Global Market Report 2022: By Type, By Application, By Technology" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Microbiome Global Market Report 2022: By Type, By Application, By Technology" report has been added to ResearchAndMarkets.com's offering.
  • The different technologies include genomics, proteomics, metabolomics and is used in inflammatory bowel disease, diabetes, multiple sclerosis, rheumatoid arthritis, others.
  • The increasing prevalence of inflammatory bowel disease (IBD) is a key factor driving the growth of the microbiome market.
  • Therefore, the increasing prevalence of inflammatory bowel disease (IBD) is expected to drive the growth of the microbiome market.

Human Microbiome Market Trends and Global Forecasts 2022-2035: Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapy - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 7, 2022
Health, General Health, Molecule, Marketing, Type, CMO, FMT, Associate, Business development, Partnership, Algorithm, Therapy, Former, Primary hyperoxaluria, FDA, Growth, Feces, Necrotizing enterocolitis, Diagnosis, Human microbiome, Infection, Adoption, Prevalence, Clinical trial, Investor, Colonoscopy, CDI, Degenerative disease, Enema, Medical device, Pharmaceutical industry, Risk management, Antibiotics, Fine chemical, Management, Innovation, Research

The "Human Microbiome Market: Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapy: Distribution by Type of Molecule, Type of Product, Target Indication, Therapeutic Areas, Supply Channels and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human Microbiome Market: Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapy: Distribution by Type of Molecule, Type of Product, Target Indication, Therapeutic Areas, Supply Channels and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • One of the key objectives of the report was to estimate the existing market size and future growth opportunity for microbiome therapeutics, diagnostics and FMTs, over the next decade.
  • What are the different initiatives undertaken by big pharma players for the development of human microbiome therapeutics in the recent past?
  • How is the current and future opportunity, related to microbiome therapeutics, diagnostics and FMT likely to be distributed across key market segments?

Xbiome Acquires Clinical-Stage Program Targeting Ulcerative Colitis

Retrieved on: 
Monday, April 25, 2022
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Drug development, Inc., FMT, Ulcerative colitis, Human microbiome, DFU, Hepatitis B virus, Microbiology, Graft-versus-host disease, Inflammation, Drug discovery, Program, Patient, LBP, Degenerative disease, AI, Algorithm, City, FDA, Industry, Acquisition, Diabetic foot ulcer, Therapy, Vaccine, Pharmaceutical industry, M201

The M201 program is designed for patients with mild to moderate ulcerative colitis.

Key Points: 
  • The M201 program is designed for patients with mild to moderate ulcerative colitis.
  • This acquisition demonstrates our commitment to developing an enhanced treatment for ulcerative colitis, as well as our broader commitment to strategically growing our pipeline to pioneer medical breakthroughs, said Yan Tan, Founder and Chief Executive Officer of Xbiome.
  • Xbiome combines a cutting-edge AI approach and microbiology platform to decode the human gut microbiome for novel drug discovery.
  • Xbiome currently has three clinical-stage programs in its pipeline focused on Ulcerative Colitis, Diabetic Foot Ulcer and Graft vs.

Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China

Retrieved on: 
Friday, January 28, 2022
Lynx, Aurealis, Growth, IND, CEO, Patient, Therapy, Graft-versus-host disease, FGF2, CSF1, GMO, FMT, Inflammation, Board, Human microbiome, Partnership, Granulation tissue, Prevalence, Growth factor, DFU, IL4, Company, Interleukin, Lactococcus lactis, Drug development, Blood, Mouth ulcer, Synthetic biology, LBP, Diabetic foot ulcer, Scholarship, Pharmaceutical industry, Vaccine

"At Aurealis we develop truly novel GMO cell and gene therapies to improve the lives of millions of patients worldwide.

Key Points: 
  • "At Aurealis we develop truly novel GMO cell and gene therapies to improve the lives of millions of patients worldwide.
  • We are extremely excited to collaborate with Aurealis to bring AUP-16 to DFU and other chronic wound patients in China.
  • Company's lead clinical asset is AUP-16, the first-in-class four-in-one cell and gene therapy drug for chronic wounds and other inflammatory degenerative diseases.
  • In June of 2021, Xbiome obtained IND approval in US for its lead program XBI-302, an orally administered FMT therapy for graft-versus-host disease (GvHD).

Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China

Retrieved on: 
Friday, January 28, 2022
Lynx, Aurealis, Growth, IND, CEO, Patient, Therapy, Graft-versus-host disease, FGF2, CSF1, GMO, FMT, Inflammation, Board, Human microbiome, Partnership, Granulation tissue, Prevalence, Growth factor, DFU, IL4, Company, Interleukin, Lactococcus lactis, Drug development, Blood, Mouth ulcer, Synthetic biology, LBP, Diabetic foot ulcer, Scholarship, Pharmaceutical industry, Vaccine

"At Aurealis we develop truly novel GMO cell and gene therapies to improve the lives of millions of patients worldwide.

Key Points: 
  • "At Aurealis we develop truly novel GMO cell and gene therapies to improve the lives of millions of patients worldwide.
  • We are extremely excited to collaborate with Aurealis to bring AUP-16 to DFU and other chronic wound patients in China.
  • Company's lead clinical asset is AUP-16, the first-in-class four-in-one cell and gene therapy drug for chronic wounds and other inflammatory degenerative diseases.
  • In June of 2021, Xbiome obtained IND approval in US for its lead program XBI-302, an orally administered FMT therapy for graft-versus-host disease (GvHD).